Acuitas Investments LLC lifted its stake in shares of NextCure, Inc. (NASDAQ:NXTC – Free Report) by 30.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 372,799 shares of the company’s stock after buying an additional 85,982 shares during the quarter. Acuitas Investments LLC owned 1.34% of NextCure worth $425,000 as of its most recent filing with the SEC.
NextCure Trading Up 6.2 %
Shares of NASDAQ:NXTC traded up $0.08 during trading on Friday, hitting $1.37. 31,865 shares of the company’s stock were exchanged, compared to its average volume of 230,945. The firm has a 50-day moving average price of $1.74 and a two-hundred day moving average price of $1.39. NextCure, Inc. has a 1-year low of $0.98 and a 1-year high of $2.57. The firm has a market cap of $38.22 million, a P/E ratio of -0.57 and a beta of 0.40.
NextCure (NASDAQ:NXTC – Get Free Report) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.02. As a group, research analysts predict that NextCure, Inc. will post -1.65 EPS for the current year.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on NXTC
NextCure Company Profile
NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.
See Also
- Five stocks we like better than NextCure
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Stocks Leading the U.S. Agriculture Comeback
- Breakout Stocks: What They Are and How to Identify Them
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Investing in the High PE Growth Stocks
- Alphabet Changes the Narrative with Its First-Ever Dividend
Want to see what other hedge funds are holding NXTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NextCure, Inc. (NASDAQ:NXTC – Free Report).
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.